目的 :分析视网膜分枝静脉阻塞不同发病阶段的激光治疗疗效 ,为临床治疗时机选择提供依据。方法 :按发病时间将患者分为病程短于 3个月但长于 1个月的A组 (2 0例 )及病程大于 3个月的B组 (2 9例 ) ,两组采用象限联合后极部格栅样光凝法。记录两组的阻塞部位、激光前后视力、眼部新生血管、黄斑病变的转归及光凝次数和光斑点数。结果 :两组在静脉阻塞部位分布、激光次数和光凝点数方面均无显著差异 ;光凝后两组视力均得到提高 ,B组基础视力较A组好约 1行 ;B组光凝前眼底新生血管总发病率为 5 1 7% ,A组为 0 ;光凝后B组新生血管消退率为 80 % ;光凝后A组和B组黄斑水肿的好转率分别为 80 %和 91 7%。两组均未见明显的并发症。结论 :在能保证随访的情况下优先对患者观察 ,如眼底出现新生血管或出血淡化则予以光凝 ;如随访不便 ,在病程 1～ 3个月之间光凝同样是有利和安全的。 OBJECTIVE: To analyze the curative effect of laser treatment in different stages of retinal vein occlusion and to provide evidence for the timing of clinical treatment. Methods: According to the onset time, patients were divided into group A (20 cases) with duration of less than 3 months but longer than 1 month and group B (29 cases) with duration of more than 3 months. Part grid-like photocoagulation. Record the obstruction of the two groups, before and after laser vision, ocular neovascularization, macular degeneration and the number of photocoagulation and spot number. Results: There was no significant difference between the two groups in the distribution of venous obstruction, the number of lasers and the number of photocoagulation points. The visual acuity of both groups was improved after photocoagulation. The basic visual acuity of group B was about 1 line better than that of group A. In group B, The total incidence of vascular disease was 51.7% in group A, and 0 in group A; the rate of neovascularization in group B was 80% after photocoagulation; the improvement rates of macular edema in group A and B were 80% and 91 7% respectively after photocoagulation. No significant complications were seen in either group. CONCLUSIONS: Patients can be preferentially observed under the condition of guaranteed follow-up. For example, neovascularization or hemorrhaging in the fundus is given photocoagulation; if inconvenient follow-up, photocoagulation is also beneficial and safe during the course of 1 to 3 months.